Molnupiravir: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), NICE (England) and SMC (Scotland) recommended or restricted molnupiravir, while CONITEC (Brazil) did not recommend it.
Where molnupiravir met resistance it was usually narrowed rather than refused: 2 of 4 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The record spans 3.2 years, opening at AWMSG (Wales) on 11 Jan 2022 and running to 16 Apr 2025.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for molnupiravir at all.
The file is active: 4 of 8 records date from 2023 or later.
5 distinct indication wordings are recorded for molnupiravir by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 8 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess molnupiravir, on 11 Jan 2022; SMC (Scotland) did not open a file until 16 Apr 2025 — a wide spread of 3.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 8 dated records fall in 2022 alone.
2 of the 6 agencies here assessed molnupiravir more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for molnupiravir.
The full ledger for molnupiravir reads 2 restricted, 2 advice, 1 not recommended and 1 recommended, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 16 Apr 2025 | NICE TA1056 | recommended (optimised) | source |
| SMC (Scotland) | 16 Apr 2025 | Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developin… | accepted (restricted) | source |
| PBAC (Australia) | 2023 | Mild to moderate Coronavirus disease (COVID-19) | Advice Provided | source |
| CONITEC (Brazil) | 12 Sep 2022 | Tratamento da Covid19 em adultos que não requerem oxigênio suplementar e que apresentam risco aumentado de progressão da… | not incorporated | source |
| CHUIKYO (Japan) | 18 Aug 2022 | ラゲブリオカプセル２００ｍｇ | listed on the NHI price list · 237 days after PMDA approval | source |
3 further decisions for molnupiravir, across 3 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 8 decisions for molnupiravir from 6 agencies, 2022 to 2025. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.